Small airways diseases, excluding asthma and COPD: An overview

European Respiratory Review

Volumn 22, Issue 128, 2013, Pages 131-147

  Burgel, Pierre Régis ^a   Bergeron, Anne ^b   de Blic, Jacques ^c   Bonniaud, Philippe ^d   Bourdin, Arnaud ^e   Chanez, Pascal ^f   Chinet, Thierry ^g   Dalphin, Jean Charles ^h   Devillier, Philippe ⁱ   Deschildre, Antoine ^j   Didier, Alain ^k   Kambouchner, Marianne ^l   Knoop, Christiane ^m   Laurent, François ⁿ   Nunes, Hilario ^l   Perez, Thierry ^j   Roche, Nicolas ^o   Tillie Leblond, Isabelle ^j   Dusser, Daniel ^a  

^a AP HP Université Paris Descartes ^*  (France)

^b SAINT LOUIS HOSPITAL   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d UNIVERSITÉ DE BOURGOGNE   (France)

^e HÔPITAL ARNAUD DE VILLENEUVE   (France)

^f HÔPITAL SAINTE MARGUERITE   (France)

^g HÔPITAL AMBROISE PARÉ   (France)

^h UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

ⁱ UPRES EA 220   (France)

^j LILLE UNIVERSITY HOSPITAL   (France)

^k UNIVERSITÉ DE TOULOUSE   (France)

^l UNIVERSITÉ PARIS 13   (France)

^m ERASME HOSPITAL   (Belgium)

ⁿ BORDEAUX UNIVERSITY HOSPITAL   (France)

^o ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

more..

Author keywords

Airway pathology; Connective tissue disease; Constrictive bronchiolitis; Drug induced lung disease; Follicular bronchiolitis; Immune deficiency

Indexed keywords

AZITHROMYCIN; BRONCHODILATING AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; DASATINIB; ERYTHROMYCIN; ETANERCEPT; GOLD; IMATINIB; MACROLIDE; PENICILLAMINE; RITUXIMAB; STEROID; TIOPRONIN; TOPOTECAN;

AIRWAY OBSTRUCTION; ALLERGIC PNEUMONITIS; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW TRANSPLANTATION; BRONCHIOLITIS; BRONCHIOLITIS OBLITERANS; BRONCHUS HYPERREACTIVITY; CLINICAL FEATURE; COMMON VARIABLE IMMUNODEFICIENCY; COMPUTER ASSISTED TOMOGRAPHY; CONNECTIVE TISSUE DISEASE; DIFFUSE PANBRONCHIOLITIS; DISEASE ASSOCIATION; ENTERITIS; ENVIRONMENTAL EXPOSURE; FARMER LUNG; FOLLICULAR BRONCHIOLITIS; FOOD INTAKE; GOLD THERAPY; GRAFT REJECTION; HISTOPATHOLOGY; HUMAN; INTERSTITIAL PNEUMONIA; JUVENILE RHEUMATOID ARTHRITIS; LOW DRUG DOSE; LUNG DISEASE; LUNG FUNCTION TEST; LUNG NON SMALL CELL CANCER; LUNG TRANSPLANTATION; NONHUMAN; OCCUPATIONAL EXPOSURE; OVARY CARCINOMA; PATHOGENESIS; PATHOPHYSIOLOGY; PSORIATIC ARTHRITIS; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; SAUROPUS ANDROGYNUS; SHRUB; SJOEGREN SYNDROME; SMALL AIRWAY DISEASE; SMOKING; THORAX RADIOGRAPHY; TREATMENT DURATION; WHOLE BODY RADIATION;

AIRWAY PATHOLOGY; CONNECTIVE TISSUE DISEASE; CONSTRICTIVE BRONCHIOLITIS; DRUG-INDUCED LUNG DISEASE; FOLLICULAR BRONCHIOLITIS; IMMUNE DEFICIENCY;

BIOPSY; BRONCHIOLES; BRONCHOGRAPHY; HUMANS; LUNG DISEASES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RESPIRATORY FUNCTION TESTS; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84878432205     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00001313     Document Type: Review

References (234)

1. Burgel PR. The role of small airways in obstructive airway diseases. Eur Respir Rev 2011; 20: 23-33.
2. Burgel PR, Bourdin A, Chanez P, et al. Update on the role of distal airways in COPD. Eur Respir Rev 2011; 20: 7-22.
3. Burgel PR, de Blic J, Chanez P, et al. Update on the roles of distal airways in asthma. Eur Respir Rev 2009; 18: 80-95.
4. Burgel PR, Montani D, Danel C, et al. A morphometric study of mucins and small airway plugging in cystic fibrosis. Thorax 2007; 62: 153-161.
5. Tiddens H, Donaldson SH, Rosenfeld M, et al. Cystic fibrosis lung disease starts in the small airways: can we treat it more effectively? Pediatric Pulmonology 2010; 45: 107-117.
6. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004; 364: 709-721.
7. Cosio M, Ghezzo H, Hogg JC, et al. The relations between structural changes in small airways and pulmonary-function tests. N Engl J Med 1978; 298: 1277-1281.
8. Ryu JH, Myers JL, Swensen SJ. Bronchiolar disorders. Am J Respir Crit Care Med 2003; 168: 1277-1292.
9. Devakonda A, Raoof S, Sung A, et al. Bronchiolar disorders: a clinico-radiological diagnostic algorithm. Chest 2010; 137: 938-951.
10. Rice A, Nicholson AG. The pathologist's approach to small airways disease. Histopathol 2009; 54: 117-133.
11. Visscher DW, Myers JL. Bronchiolitis. The pathologist's perspective. Proc Am Thor Soc 2006; 3: 41-47.
12. Yousem SA. Small airways disease. Pathol Annu 1991; 26: 109-143.
13. Yousem SA, Colby TV, Carrington CB. Follicular bronchitis/ bronchiolitis. Hum Pathol 1985; 16: 700-706.
14. Park JH, Levinson AI. Granulomatous-lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID). Clin Immunol 2010; 134: 97-103.
15. Masuda T, Ishikawa Y, Akasaka Y, et al. Follicular bronchiolitis associated with Legionella pneumophilia infection. Pediatr Pathol Mol Med 2002; 21: 517-524.
16. Burgel PR, Nadel JA. Epidermal growth factor receptor-mediated innate immune responses and their roles in airway diseases. Eur Respir J 2008; 32: 1068-1081.
17. Fukuoka J, Franks TJ, Colby TV, et al. Peribronchiolar metaplasia: a common histologic lesion in diffuse lung disease and a rare cause of interstitial lung disease: clinicopathologic features of 15 cases. Am J Surg Pathol 2005; 29: 948-954.
18. Rowan C, Hansell DM, Renzoni E, et al. Diffuse cystic lung disease of unexplained cause with coexistent small airway disease: a possible cause relationship? Am J Surg Pathol 2012; 36: 228-234.
19. Galbán CJ, Han MK, Boes JL, et al. Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med 2012; 18: 1711-1715.
20. Hansell DM, Rubens MB, Padley SP, et al. Obliterative bronchiolitis: individual CT signs of small airways disease and functional correlation. Radiology 1997; 203: 721-726.
21. Tillie-Leblond, Crestani B, Perez T, et al. Voies aériennes distales et maladies de système [The distal airways is systemic disease.]. Rev Mal Resp 2012; 29: 1254-1263.
22. Martin C, Frija J, Burgel PR. Dysfunctional lung anatomy and small airways degeneration in COPD. Int J COPD 2013; 8: 7-13.
23. Larranaga C, Kajon A, Villagra E, et al. Adenovirus surveillance on children hospitalized for acute lower respiratory infections in Chile (1988-1996). J Med Virol 2000; 60: 342-346.
24. Videla C, Carballal G, Kajon A. Genomic analysis of adenovirus isolated from Argentinian children with acute lower respiratory infections. J Clin Virol 1999; 14: 67-71.
25. Castro-Rodriguez JA, Daszenies C, Garcia M, et al. Adenovirus pneumonia in infants and factors for developing bronchiolitis obliterans: a 5-year follow-up. Pediatr Pulmonol 2006; 41: 947-953.
26. Lang WR, Howden CW, Laws J, et al. Bronchopneumonia with serious sequelae in children with evidence of adenovirus type 21 infection. Br Med J 1969; 1: 73-79.
27. Daxbock F, Brunner G, Popper H, et al. A case of lung transplantation following Mycoplasma pneumoniae infection. Eur J Clin Microbiol Infect Dis 2002; 21: 318-322.
28. Kim CK, Kim SW, Kim JS, et al. Bronchiolitis obliterans in the 1990s in Korea and the United States. Chest 2001; 120: 1101-1106.
29. Villarreal Garcia-Lomas M, Vargas Nunez JA, Romero Pizarro Y, et al. Bronquiolitos obliterante con neumońi{dotless}a organizativa asociada a infección por Mycoplasma pneumoniae [Bronchiolitis obliterans with organizing pneumonia associated with Myco-plasma pneumoniae infection.]. Rev Clin Esp 2002; 202: 519-520.
30. Colom AJ, Teper AM, Vollmer WM, et al. Risk factors for the development of bronchiolitis obliterans in children with bronch-iolitis. Thorax 2006; 61: 503-506.
31. Fischer GB, Sarria EE, Mattiello R, et al. Post infectious bronchiolitis obliterans in children. Paediatr Respir Rev 2010; 11: 233-239.
32. Cazzato S, Poletti V, Bernardi F, et al. Airway inflammation and lung function decline in childhood post-infectious bronchiolitis obliterans. Pediatr Pulmonol 2008; 43: 381-390.
33. Teper AM, Kofman CD, Maffey AF, et al. Lung function in infants with chronic pulmonary disease after severe adenoviral illness. J Pediatr 1999; 134: 730-733.
34. Cordier JF. Organising pneumonia. Thorax 2000; 55: 318-328.
35. Hall WJ, Hall CB, Speers DM. Respiratory syncytial virus infection in adults: clinical, virologic, and serial pulmonary function studies. Ann Intern Med 1978; 88: 203-205.
36. Rollins S, Colby T, Clayton F. Open lung biopsy in Mycoplasma pneumoniae pneumonia. Arch Pathol Lab Med 1986; 110: 34-41.
37. Sato P, Madtes DK, Thorning D, et al. Bronchiolitis obliterans caused by Legionella pneumophila. Chest 1985; 87: 840-842.
38. Kuru T, Lynch JP 3rd. Nonresolving or slowly resolving pneumonia. Clin Chest Med 1999; 20: 623-651.
39. White ES, Tazelaar HD, Lynch JP 3rd. Bronchiolar complications of connective tissue diseases. Semin Respir Crit Care Med 2003; 24: 543-566.
40. Hatron PY, Tillie-Leblond I, Launay D, et al. Pulmonary manifestations of Sjögren's syndrome. Presse Med 2011; 40: e49-e64.
41. Hayakawa H, Sato A, Imokawa S, et al. Bronchiolar disease in rheumatoid arthritis. Am J Respir Crit Care Med 1996; 154: 1531-1536.
42. Vandenplas O, Casel S, Delos M, et al. Granulomatous bronchiolitis associated with Crohn's disease. Am J Respir Crit Care Med 1998; 158: 1676-1679.
43. Nunes H, Brillet PY, Valeyre D, et al. Imaging in sarcoidosis. Semin Respir Crit Care Med 2007; 28: 102-120.
44. Tanaka N, Kim JS, Newell JD, et al. Rheumatoid arthritis-related lung diseases: CT findings. Radiology 2004; 232: 81-91.
45. Cortet B, Perez T, Roux N, et al. Pulmonary function tests and high resolution computed tomography of the lungs in patients with rheumatoid arthritis. Ann Rheum Dis 1997; 56: 596-600.
46. Devaraj A, Wells AU, Hansell DM. Computed tomographic imaging in connective tissue diseases. Semin Respir Crit Care Med 2007; 28: 389-397.
47. Franquet T, Diaz C, Domingo P, et al. Air trapping in primary Sjogren syndrome: correlation of expiratory CT with pulmonary function tests. J Comput Assist Tomogr 1999; 23: 169-173.
48. Franquet T, Gimenez A, Monill JM, et al. Primary Sjogren's syndrome and associated lung disease: CT findings in 50 patients. AJR Am J Roentgenol 1997; 169: 655-658.
49. Franquet T, Muller NL. Disorders of the small airways: high-resolution computed tomographic features. Semin Respir Crit Care Med 2003; 24: 437-444.
50. Hassan WU, Keaney NP, Holland CD, et al. High resolution computed tomography of the lung in lifelong non-smoking patients with rheumatoid arthritis. Ann Rheum Dis 1995; 54: 308-310.
51. Ito I, Nagai S, Kitaichi M, et al. Pulmonary manifestations of primary Gougerot-Sjögren's Syndrome. A clinical, radiologic, and pathologic study. Am J Respir Crit Care Med 2005; 171: 632-638.
52. Perez T, Remy-Jardin M, Cortet B. Airways involvement in rheumatoid arthritis: clinical, functional, and HRCT findings. Am J Respir Crit Care Med 1998; 157: 1658-1665.
53. Taouli B, Brauner MW, Mourey I, et al. Thin-section chest CT findings of primary Sjogren's syndrome: correlation with pulmonary function. Eur Radiol 2002; 12: 1504-1511.
54. Watanabe M, Naniwa T, Hara M, et al. Pulmonary manifestations in Sjogren's syndrome: correlation analysis between chest computed tomographic findings and clinical subsets with poor prognosis in 80 patients. J Rheumatol 2010; 373: 65-73.
55. Devouassoux G, Cottin V, Liote H, et al. Characterisation of severe obliterative bronchiolitis in rheumatoid arthritis. Eur Respir J 2009; 33: 1053-1061.
56. Papiris SA, Saetta M, Turato G, et al. CD4-positive T-lympho-cytes infiltrate the bronchial mucosa of patients with Gougerot-Sjögren's syndrome. Am J Respir Crit Care Med 1997; 156: 637-641.
57. Amin K, Lúdvíksdóttir D, Janson C, et al. Bronchial hyper-responsiveness. Inflammation and structural changes in the airways of patients with primary Sjögren's syndrome. Respir Med 2001; 95: 904-910.
58. Nakanishi M, Fukuoka J, Tanaka T, et al. Small airway disease associated with Sjögren's syndrome: clinico-pathological correlations. Respir Med 2011; 105: 1931-1938.
59. Fortoul TI, Cano-Valle F, Oliva E, et al. Follicular bronchiolitis in association with connective tissue diseases. Lung 1985; 163: 305-314.
60. Newball HH, Brahim SA. Chronic obstructive airway disease in patients with Sjögren's syndrome. Am Rev Respir Dis 1977; 115: 295-304.
61. Mialon P, Barthélémy L, Sébert P, et al. A longitudinal study of lung impairment in patients with primary Sjögren's syndrome. Clin Exp Rheumatol 1997; 15: 349-354.
62. Gudbjornsson B, Hedenstrom H, Stalenheim G, et al. Bronchial hyperresponsiveness to methacholine in patients with primary Sjogren's syndrome. Ann Rheum Dis 1991; 50: 36-40.
63. La Corte R, Potena A, Bajocchi G, et al. Increased bronchial responsiveness in primary Sjogren's syndrome. A sign of tracheobronchial involvement. Clin Exp Rheumatol 1991; 9: 125-130.
64. Potena A, La Corte R, Fabbri LM, et al. Increased bronchial responsiveness in primary and secondary Sjogren's syndrome. Eur Respir J 1990; 3: 548-553.
65. Ludviksdottir D, Janson C, Bjornsson E, et al. Different airway responsiveness profiles in atopic asthma, nonatopic asthma, and Sjogren's syndrome. BHR Study Group. Bronchial hyperrespon-siveness. Allergy 2000; 55: 259-265.
66. Borie R, Schneider S, Debray MP, et al. Severe chronic bronchiolitis as the presenting feature of primary Sjögren's syndrome. Respir Med 2011; 105: 130-136.
67. Koyama M, Johkoh T, Honda O, et al. Pulmonary involvement in primary Sjogren's syndrome: spectrum of pulmonary abnormalities and computed tomography findings in 60 patients. J Thorac Imaging 2001; 16: 290-296.
68. Lohrmann C, Uhl M, Warnatz K, et al. High-resolution CT imaging of the lung for patients with primary Sjogren's syndrome. Eur Radiol 2004; 52: 137-143.
69. Papiris SA, Maniati M, Constantopoulos SH, et al. Lung involvement in primary Sjogren's syndrome is mainly related to the small airway disease. Ann Rheum Dis 1999; 58: 61-64.
70. Uffmann M, Kiener HP, Bankier AA, et al. Lung manifestation in asymptomatic patients with primary Sjogren syndrome: assessment with high resolution CT and pulmonary function tests. J Thorac Imaging 2001; 16: 282-289.
71. Stalenheim G, Gudbjornsson B. Anti-inflammatory drugs do not alleviate bronchial hyperreactivity in Sjogren's syndrome. Allergy 1997; 52: 423-427.
72. Meijer JM, Pijpe J, Vissink A, et al. Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment. Ann Rheum Dis 2009; 68: 284-285.
73. Puechal X, Bienvenu T, Genin E, et al. Mutations of the cystic fibrosis gene in patients with bronchiectasis associated with rheumatoid arthritis. Ann Rheum Dis 2011; 70: 653-659.
74. Puechal X, Fajac I, Bienvenu T, et al. Increased frequency of cystic fibrosis deltaF508 mutation in bronchiectasis associated with rheumatoid arthritis. Eur Respir J 1999; 13: 1281-1287.
75. Bienvenu T, Sermet-Gaudelus I, Burgel PR, et al. CFTR channel dysfunction in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2010; 181: 1078-1084.
76. Geddes DM, Webley M, Emerson PA. Airways obstruction in rheumatoid arthritis. Ann Rheum Dis 1979; 38: 222-225.
77. Howling SJ, Hansell DM, Wells AU, et al. Follicular bronchiolitis: thin-section CT and histologic findings. Radiology 1999; 212: 637-642.
78. Leslie KO, Trahan S, Gruden J. Pulmonary pathology of the rheumatic diseases. Semin Respir Crit Care Med 2007; 28: 369-378.
79. Mori S, Koga Y, Sugimoto M. Small airway obstruction inpatients with rheumatoid arthritis. Mod Rheumatol 2011; 21: 164-173.
80. Stein HB, Patterson AC, Offer RC, et al. Adverse effects of D-penicillamine in rheumatoid arthritis. Ann Intern Med 1980; 92: 24-29.
81. Tomioka R, King TE Jr. Gold-induced pulmonary disease: clinical features, outcome, and differentiation from rheumatoid lung disease. Am J Respir Crit Care Med 1997; 155: 1011-1020.
82. Homma S, Kawabata M, Kishi K, et al. Diffuse panbronchiolitis in rheumatoid arthritis. Eur Respir J 1998; 12: 444-452.
83. Tsuchiya Y, Takayanagi N, Sugiura H, et al. Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J 2011; 37: 1411-1417.
84. Cortot AB, Cottin V, Miossec P, et al. Improvement of refractory rheumatoid arthritis-associated constrictive bronchiolitis with etanercept. Respir Med 2005; 99: 511-514.
85. Hoffmann RM, Kruis W. Rare extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 140-147.
86. Mahadeva R, Walsh G, Flower CD, et al. Clinical and radiological characteristics of lung disease in inflammatory bowel disease. Eur Respir J 2000; 15: 41-48.
87. Eaton TE, Lambie N, Wells AU. Bronchiectasis following colectomy for Crohn's disease. Thorax 1998; 53: 529-531.
88. Tzanakis N, Samiou M, Bouros D, et al. Small airways function in patients with inflammatory bowel disease. Am J Respir Crit Care Med 1998; 157: 382-386.
89. Camus P, Piard F, Ashcroft T, et al. The lung in inflammatory bowel disease. Medicine (Baltimore) 1993; 72: 151-183.
90. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21: 297-310.
91. Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report-2010. J Heart Lung Transplant 2010; 29: 1104-1118.
92. Copeland CAF, Snyder LD, Zaas DW, et al. Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients. Am J Respir Crit Care Med 2010; 182: 784-789.
93. Vanaudenaerde BM, Meyts I, Vos R, et al. A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Resp J 2008; 32: 832-843.
94. Agarwal S, Cunningham-Rundles C. Autoimmunity in common variable immunodeficiency. Curr Allergy Asthma Rep 2009; 9: 347-352.
95. Hachem RR, Khalifah AP, Chakinala MM, et al. The significance of a single episode of minimal acute rejection after lung transplantation. Transplantation 2005; 80: 1406-1413.
96. Hopkins PM, Aboyoun CL, Chhajed PN, et al. Association of minimal rejection in lung transplant recipients with obliterative bronchiolitis. Am J Respir Crit Care Med 2004; 170: 1022-1026.
97. Khalifah AP, Hachem RR, Chakinala MM, et al. Minimal acute rejection after lung transplantation: a risk for bronchiolitis obliterans syndrome. Am J Transplant 2005; 5: 2022-2030.
98. Knoop C, Estenne M. Chronic allograft dysfunction. Clin Chest Med 2011; 32: 311-326.
99. Girnita AL, Duquesnoy R, Yousem SA, et al. HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. Am J Transplant 2005; 5: 131-138.
100. Snyder LD, Finlen-Copeland CA, Turbyfill WJ, et al. Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am J Respir Crit Care Med 2010; 181: 1391-1396.
101. Tamm M, Aboyoun CL, Chhajed PN, et al. Treated cytomega-lovirus pneumonia is not associated with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2004; 170: 1120-1123.
102. Kumar D, Erdman D, Keshavjee S, et al. Clinical impact of community-acquired respiratory viruses on bronchiolitis oblit-erans after lung transplant. Am J Transplant 2005; 5: 2031-2036.
103. Vu DL, Bridevaux PO, Aubert JD, et al. Respiratory viruses in lung transplant recipients: a critical review and pooled analysis of clinical studies. Am J Transplant 2011; 11: 1071-1078.
104. Cantu E, Appel JZ, Hartwig MG, et al. Early fundoplication prevents chronic allograft dysfunction in patients with gastro-esophageal reflux disease. Ann Thorac Surg 2004; 78: 1142-1151.
105. Davis RD, Lau CL, Eubanks S, et al. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. J Thorac Cardiovasc Surg 2003; 125: 533-542.
106. Hartwig MG, Anderson DJ, Onaitis MW, et al. Fundoplication after lung transplantation prevents the allograft dysfunction associated with reflux. Ann Thorac Surg 2011; 92: 462-469.
107. Saini D, Weber J, Ramachandran S, et al. Alloimmunity-induced autoimmunity as a potential mechanism in the pathogenesis of chronic rejection of human lung allografts. J Heart Lung Transplant 2011; 30: 624-631.
108. Jaramillo A, Smith CR, Maruyama T, et al. Anti-HLA class I antibody binding to airway epithelial cells induces production of fibrogenic growth factors and apoptotic cell death: a possible mechanism for bronchiolitis obliterans syndrome. Hum Immunol 2003; 64: 521-529.
109. Bharat A, Saini D, Steward N, et al. Antibodies to self-antigens predispose to primary lung allograft dysfunction and chronic rejection. Ann Thorac Surg 2010; 90: 1094-1100.
110. Nakajima T, Palchevsky V, Perkins DL, et al. Lung transplantation: infection, inflammation, and the microbiome. Semin Immunopathol 2011; 33: 135-156.
111. Bobadilla JL, Jankowska-Gan E, Xu Q, et al. Reflux-induced collagen type v sensitization potential mediator of bronchiolitis obliterans syndrome. Chest 2010; 138: 363-370.
112. Neujahr DC, Larsen CP. Regulatory T cells in lung transplantation-an emerging concept. Semin Immunopathol 2011; 33: 117-127.
113. Borthwick LA, Sunny SS, Oliphant V, et al. Pseudomonas aeruginosa accentuates epithelial-to-mesenchymal transition in the airway. Eur Respir J 2011; 37: 1237-1247.
114. Estenne M, Van Muylem A, Knoop C, et al. Detection of obliterative bronchiolitis after lung transplantation by indexes of ventilation distribution. Am J Respir Crit Care Med 2000; 162: 1047-1051.
115. Van Muylem A, Knoop C, Estenne M. Early detection of chronic pulmonary allograft dysfunction by exhaled biomarkers. Am J Respir Crit Care Med 2007; 175: 731-736.
116. Neurohr C, Huppmann P, Samweber B, et al. Prognostic value of bronchoalveolar lavage neutrophilia in stable lung transplant recipients. J Heart Lung Transplant 2009; 28: 468-474.
117. Macpherson RI, Cumming GR, Chernick V. Unilateral hyperlu-cent lung: a complication of viral pneumonia. J Can Assoc Radiol 1969; 20: 225-231.
118. Monchaud C, Marquet P. Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: Part I. Clin Pharmacokinet 2009; 48: 419-462.
119. Monchaud C, Marquet P. Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: Part II. Clin Pharmacokinet 2009; 48: 489-516.
120. Verleden GM, Vanaudenaerde BM, Dupont LJ, et al. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2006; 174: 566-570.
121. Vos R, Vanaudenaerde BM, Verleden SE, et al. A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur Respir J 2011; 37: 164-172.
122. Johnson BA, Iacono AT, Zeevi A, et al. Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med 2003; 167: 1271-1278.
123. Li YJ, Gottlieb J, Ma DH, et al. Graft-protective effects of the HMG-CoA reductase inhibitor pravastatin after lung transplantation - a propensity score analysis with 23 years of follow-up. Transplantation 2011; 92: 486-492.
124. Groetzner J, Wittwer T, Kaczmarek I, et al. Conversion to sirolimus and mycophenolate can attenuate the progression bronchiolitis obliterans syndrome and improves renal lung transplantation function after lung transplantation. Transplantation 2006; 81: 355-360.
125. Robertson AGN, Griffin SM, Murphy DM, et al. Targeting allograft injury and inflammation in the management of post-lung transplant bronchiolitis obliterans syndrome. Am J Transplant 2009; 9: 1272-1278.
126. Sarahrudi K, Estenne M, Corris P, et al. International experience with conversion from cyclosporine to tacrolimus for acute and chronic lung allograft rejection. J Thorac Cardiovasc Surg 2004; 127: 1126-1132.
127. Yates B, Murphy DM, Forrest IA, et al. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2005; 172: 772-775.
128. Fisher AJ, Rutherford RM, Bozzino J, et al. The safety and efficacy of total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant 2005; 5: 537-543.
129. Kawut SM, Lederer DJ, Keshavjee S, et al. Outcomes after lung retransplantation in the modern era. Am J Respir Crit Care Med 2008; 177: 114-120.
130. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956.
131. Chien JW, Duncan S, Williams KM, et al. Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplant-ation-an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2010; 16: Suppl. 1, S106-S114.
132. Au BK, Au MA, Chien JW. Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011; 17: 1072-1078.
133. Yousem SA. The histological spectrum of pulmonary graft-versus-host disease in bone marrow transplant recipients. Hum Pathol 1995; 26: 668-675.
134. Holbro A, Lehmann T, Girsberger S, et al. Lung histology predicts outcome of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013 [In press DOI 10.1016/J.BBMT.2013.03.017]
135. Chan CK, Hyland RH, Hutcheon MA, et al. Small-airways disease in recipients of allogeneic bone marrow transplants. An analysis of 11 cases and a review of the literature. Medicine (Baltimore) 1987; 66: 327-340.
136. Clark JG, Crawford SW, Madtes DK, et al. Obstructive lung disease after allogeneic marrow transplantation. Clinical presentation and course. Ann Intern Med 1989; 111: 368-376.
137. Dudek AZ, Mahaseth H, DeFor TE, et al. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant 2003; 9: 657-666.
138. Marras TK, Chan CK, Lipton JH, et al. Long-term pulmonary function abnormalities and survival after allogeneic marrow transplantation. Bone Marrow Transplant 2004; 33: 509-517.
139. Marras TK, Szalai JP, Chan CK, et al. Pulmonary function abnormalities after allogeneic marrow transplantation: a systematic review and assessment of an existing predictive instrument. Bone Marrow Transplant 2002; 30: 599-607.
140. Palmas A, Tefferi A, Myers JL, et al. Late-onset noninfectious pulmonary complications after allogeneic bone marrow transplantation. Br J Haematol 1998; 100: 680-687.
141. Philit F, Wiesendanger T, Archimbaud E, et al. Post-transplant obstructive lung disease ("bronchiolitis obliterans"): a clinical comparative study of bone marrow and lung transplant patients. Eur Respir J 1995; 8: 551-558.
142. Erard V, Chien JW, Kim HW, et al. Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses. J Infect Dis 2006; 193: 1619-1625.
143. +T cells, the cytokines they generate, and GVHD: something old and something new. Blood 2011; 117: 3268-3276.
144. Schroeder MA, DiPersio JF. Mouse models of graft-versus-host disease: advances and limitations. Dis Model Mech 2011; 4: 318-333.
145. Streichenberger N, Peyrol S, Philit F, et al. Constrictive bronchiolitis obliterans. Characterisation of fibrogenesis and lysyl oxidase expression patterns. Virchows Arch 2001; 439: 78-84.
146. Lorillon G, Robin M, Meignin V, et al. Rituximab in bronchiolitis obliterans after haematopoietic stem cell transplantation. Eur Respir J 2011; 38: 470-472.
147. Chien JW, Zhao LP, Hansen JA, et al. Genetic variation in bactericidal/permeability-increasing protein influences the risk of developing rapid airflow decline after hematopoietic cell transplantation. Blood 2006; 107: 2200-2207.
148. Panoskaltsis-Mortari A, Tram KV, Price AP, et al. A new murine model for bronchiolitis obliterans post-bone marrow transplant. Am J Respir Crit Care Med 2007; 176: 713-723.
149. Bergeron A, Godet C, Chevret S, et al. Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis. Bone Marrow Transplant 2012 [In press DOI: 10.1038/ bmt.2012.241].
150. St John RC, Gadek JE, Tutschka PJ, et al. Analysis of airflow obstruction by bronchoalveolar lavage following bone marrow transplantation. Implications for pathogenesis and treatment. Chest 1990; 98: 600-607.
151. Rochat I, Posfay-Barbe KM, Kumar N, et al. Bronchoalveolar cytology for diagnosing pulmonary GVHD after bone marrow transplant in children. Pediatr Pulmonol 2008; 43: 697-702.
152. Gulbahce HE, Baker KS, Kumar P, et al. Atypical cells in bronchoalveolar lavage specimens from bone marrow transplant recipients. A potential pitfall. Am J Clin Pathol 2003; 120: 101-106.
153. Bashoura L, Gupta S, Jain A, et al. Inhaled corticosteroids stabilize constrictive bronchiolitis after hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 41: 63-67.
154. Bergeron A, Belle A, Chevret S, et al. Combined inhaled steroids and bronchodilatators in obstructive airway disease after allo-geneic stem cell transplantation. Bone Marrow Transplant 2007; 39: 547-553.
155. Wolff D, Gerbitz A, Ayuk F, et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant 2010; 16: 1611-1628.
156. Koenecke C, Hertenstein B, Schetelig J, et al. Solid organ transplantation after allogeneic hematopoietic stem cell transplantation: a retrospective, multicenter study of the EBMT. Am J Transplant 2010; 10: 1897-1906.
157. Chapel H, Cunningham-Rundles C. Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. Br J Haematol 2009; 145: 709-727.
158. Cunningham-Rundles C. How I treat common variable immune deficiency. Blood 2010; 116: 7-15.
159. Nicholson AG, Wotherspoon AC, Diss TC, et al. Reactive pulmonary lymphoid disorders. Histopathology 1995; 26: 405-412.
160. Chapel H, Lucas M, Lee M, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 2008; 112: 277-286.
161. Bouvry D, Mouthon L, Brillet PY, et al. Granulomatosis-associated common variable immunodeficiency disorder: a case control study versus sarcoidosis. Eur Resp J 2013; 41: 115-122.
162. Kaufman J, Komorowski R. Bronchiolitis obliterans organizing pneumonia in common variable immunodeficiency syndrome. Chest 1991; 100: 552-553.
163. Wislez M, Sibony M, Naccache JM, et al. Organizing pneumonia related to common variable immunodeficiency. Case report and literature review. Respiration 2000; 67: 467-470.
164. Cunningham-Rundles C. Autoimmune manifestations in common variable immunodeficiency. J Clin Immunol 2008; 28: Suppl. 1, S42-S45.
165. Cunningham-Rundles C. Autoimmunity in primary immune deficiency: taking lessons from our patients. Clin Exp Immunol 2011; 164: Suppl. 2, S6-S11.
166. Bates CA, Ellison MC, Lynch DA, et al. Granulomatous-lymphocytic lung disease shortens survival in common variable immunodeficiency. J Allergy Clin Immunol 2004; 114: 415-421.
167. Gregersen S, Aalokken TM, Mynarek G, et al. High resolution computed tomography and pulmonary function in common variable immunodeficiency. Respir Med 2009; 103: 873-880.
168. van Zeggeren L, van de Ven AA, Terheggen-Lagro SW, et al. High-resolution computed tomography and pulmonary function in children with common variable immunodeficiency. Eur Respir J 2011; 38: 1437-1443.
169. Davies CW, Juniper MC, Gray W, et al. Lymphoid interstitial pneumonitis associated with common variable hypogammaglo-bulinaemia treated with cyclosporin A. Thorax 2000; 55: 88-90.
170. Hatab AZ, Ballas ZK. Caseating granulomatous disease in common variable immunodeficiency treated with infliximab. J Allergy Clin Immunol 2005; 116: 1161-1162.
171. Kudoh S, Keicho N. Diffuse panbronchiolitis. Clin Chest Med 2012; 33: 297-305.
172. Poletti V, Casoni G, Chilosi M, et al. Diffuse panbronchiolitis. Eur Resp J 2006; 28: 862-871.
173. Akira M, Kitatani F, Lee YS, et al. Diffuse panbronchiolitis: evaluation with high-resolution CT. Radiology 1988; 168: 433-438.
174. Kim JH, Juang KH, Han JH, et al. Relation of epidermal growth factor receptor expression to mucus hypersecretion in diffuse panbronchiolitis. Chest 2004; 126: 888-895.
175. Kamio K, Matsushita I, Hijikata M, et al. Promoter analysis and aberrant expression of the MUC5B gene in diffuse panbronch-iolitis. Am J Respir Crit Care Med 2005; 171: 949-957.
176. Keicho N, Hijikata M. Genetic predisposition to diffuse panbronchiolitis. Respirology 2011; 16: 581-588.
177. Friedlander AL, Albert RK. Chronic macrolide therapy in inflammatory airways diseases. Chest 2010; 138: 1202-1212.
178. Yamada G, Igarashi T, Itoh E, et al. Centrilobular nodules correlate with air trapping in diffuse panbronchiolitis during erythromycin therapy. Chest 2001; 120: 198-202.
179. Hanon S, Verbanck S, Schuermans D, et al. Evidence of improved small airways function after azithromycin treatment in diffuse panbronchiolitis. Respiration 2012; 84: 75-79.
180. Camus P, Bonniaud P, Fanton A, et al. Drug-induced and iatrogenic infiltrative lung disease. Clin Chest Med 2004; 25: 479-519.
181. Epler GR. Drug-induced bronchiolitis obliterans organizing pneumonia. Clin Chest Med 2004; 25: 89-94.
182. Babu KS, Marshall BG. Drug-induced airway diseases. Clin Chest Med 2004; 25: 113-122.
183. Brewerton D. D-Penicillamine. Br Med J 1976; 2: 1507.
184. Epler GR, Snider GL, Gaensler EA, et al. Bronchiolitis and bronchitis in connective tissue disease. A possible relationship to the use of penicillamine. JAMA 1979; 242: 528-532.
185. Wolfe F, Schurle DR, Lin JJ, et al. Upper and lower airway disease in penicillamine treated patients with rheumatoid arthritis. J Rheumatol 1983; 10: 406-410.
186. Boehler A, Vogt P, Speich R, et al. Bronchiolitis obliterans in a patient with localized scleroderma treated with D-penicillamine. Eur Respir J 1996; 9: 1317-1319.
187. Schwartzman KJ, Bowie DM, Yeadon C, et al. Constrictive bronchiolitis obliterans following gold therapy for psoriatic arthritis. Eur Respir J 1995; 8: 2191-2193.
188. Pegg SJ, Lang BA, Mikhail EL, et al. Fatal bronchiolitis obliterans in a patient with juvenile rheumatoid arthritis receiving chrysotherapy. J Rheumatol 1994; 21: 549-551.
189. Demaziere A, Maugars Y, Chollet S, et al. Non-fatal bronchiolitis obliterans possibly associated with tiopronin. A case report with long-term follow-up. Br J Rheumatol 1993; 32: 172-174.
190. Massin F, Fur A, Reybet-Degat O, et al. La pneumopathie du busulfan [Busulfan-induced pneumopathy]. Rev Mal Respir 1987; 4: 3-10.
191. Ringden O, Remberger M, Ruutu T, et al. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. Blood 1999; 93: 2196-2201.
192. Santo Tomas LH, Loberiza FR Jr, Klein JP, et al. Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem-cell transplantation for leukemia. Chest 2005; 128: 153-161.
193. Lai RS, Chiang AA, Wu MT, et al. Outbreak of bronchiolitis obliterans associated with consumption of Sauropus androgynus in Taiwan. Lancet 1996; 348: 83-85.
194. Hsiue TR, Guo YL, Chen KW, et al. Dose-response relationship and irreversible obstructive ventilatory defect in patients with consumption of Sauropus androgynus. Chest 1998; 113: 71-76.
195. Oonakahara K, Matsuyama W, Higashimoto I, et al. Outbreak of bronchiolitis obliterans associated with consumption of Sauropus androgynus in Japan - alert of food-associated pulmonary disorders from Japan. Respiration 2005; 72: 221.
196. Svetlecic J, Molteni A, Herndon B. Bronchiolitis obliterans induced by intratracheal papaverine: a novel animal model. Lung 2004; 182: 119-134.
197. Edgerton CC, Gilman M, Roth BJ. Topotecan-induced bronchio-litis. South Med J 2004; 97: 699-701.
198. Bergeron A, Rea D, Levy V, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med 2007; 176: 814-818.
199. Mukhopadhyay S, Katzenstein AL. Pulmonary disease due to aspiration of food and other particulate matter: a clinicopatho-logic study of 59 cases diagnosed on biopsy or resection specimens. Am J Surg Pathol 2007; 31: 752-759.
200. Janoski MM, Raymond GS, Puttagunta L, et al. Psyllium aspiration causing bronchiolitis: radiographic, high-resolution CT, and pathologic findings. AJR Am J Roentgenol 2000; 174: 799-801.
201. Girard M, Lacasse Y, Cormier Y. Hypersensitivity pneumonitis. Allergy 2009; 64: 322-334.
202. Bourke SJ, Dalphin JC, McSharry CP, et al. Hypersensitivity pneumonitis: current concepts. Eur Respir J 2001; 18: 81s-92s.
203. Selman M, Perez-Padilla R. Airflow obstruction and airway lesions in hypersensitivity pneumonitis. Clin Chest Med 1993; 14: 699-714.
204. Selman M, Vargas MH. Airway involvement in hypersensitivity pneumonitis. Curr Opin Pulm Med 1998; 4: 9-15.
205. Hanak V, Golbin JM, Ryu JH. Causes and presenting features in 85 consecutive patients with hypersensitivity pneumonitis. Mayo Clin Proc 2007; 82: 812-816.
206. Glazer CS, Martyny JW, Lee B, et al. Nontuberculous mycobac-teria in aerosol droplets and bulk water samples from therapy pools and hot tubs. J Occup Environ Hyg 2007; 4: 831-840.
207. Hanak V, Kalra S, Aksamit TR, et al. Hot tub lung: presenting features and clinical course of 21 patients. Respir Med 2006; 100: 610-615.
208. Hartman TE, Jensen E, Tazelaar HD, et al. CT findings of granulomatous pneumonitis secondary to Mycobacterium avium intracellulare inhalation: "hot tub lung". Am J Roentgenol 2007; 188: 1050-1053.
209. Sood A, Sreedhar R, Kulkarni P, et al. Hypersensitivity pneumonitis-like granulomatous lung disease with nontubercu-lous mycobacteria from exposure to hot water aerosols. Environ Health Perspect 2007; 115: 262-266.
210. Tillie-Leblond I, Grenouillet F, Reboux G, et al. Hypersensitivity pneumonitis associated to metalworking fluids contaminated by mycobacteria. Eur Respir J 2011; 37: 640-647.
211. Lacasse Y, Selman M, Costabel U, et al. Clinical diagnosis of hypersensitivity pneumonitis. Am J Respir Crit Care Med 2003; 168: 952-958.
212. Lacasse Y, Selman M, Costabel U, et al. Classification of hypersensitivity pneumonitis: a hypothesis. Int Arch Allergy Immunol 2009; 149: 161-166.
213. Coleman A, Colby TV. Histologic diagnosis of extrinsic allergic alveolitis. Am J Surg Pathol 1988; 12: 514-518.
214. Iwata M, Colby TV, Kitaichi M. Diffuse panbronchiolitis: diagnosis and distinction from various pulmonary diseases with centrilobular interstitial foam cell accumulations. Hum Pathol 1994; 25: 357-363.
215. Perez-Padilla R, Gaxiola M, Salas J, et al. Bronchiolitis in chronic pigeon breeder's disease: morphologic evidence of a spectrum of small airway lesions in hypersensitivity pneumonitis induced by avian antigens. Chest 1996; 110: 371-377.
216. Reyes CN, Wenzel FJ, Lawton BR, et al. The pulmonary pathology of farmer's lung disease. Chest 1982; 81: 142-146.
217. Kawanami O, Basset F, Barrios R, et al. Hypersensitivity pneumonitis in man: light- and electron-microscopic studies of 18 lung biopsies. Am J Pathol 1983; 110: 275-289.
218. Hodgson MJ, Parkinson DK, Harf M. Chest X rays in hypersensitivity: a meta-analysis of secular trend. Am J Ind Med 1989; 16: 45-53.
219. Hansell DM, Wells AU, Padley SP, et al. Hypersensitivity pneumonitis: correlation of individual CT patterns with functional abnormalities. Radiology 1996; 199: 123-128.
220. Remy-Jardin M, Remy J, Wallaert B, et al. Subacute and chronic bird breeder hypersensitivity pneumonitis: sequential evaluation with CT and correlation with lung function tests and bronch-oalveolar lavage. Radiology 1993; 189: 111-118.
221. Cormier Y, Brown M, Worthy S, et al. High-resolution computed tomographic characteristics in acute farmers' lung and in its follow-up. Eur Respir J 2000; 16: 56-60.
222. Bourke SJ, Anderson K, Lynch PP, et al. Chronic simple bronchitis in pigeon fanciers: relationship of cough with expectoration to avian exposure and pigeon breeder's disease. Chest 1989; 95: 598-601.
223. Bourke SJ, Carter R, Anderson K, et al. Obstructive airway disease in non-smoking subjects with pigeon fanciers' lung. Clin Exp Allergy 1989; 19: 629-632.
224. Dalphin JC, Debieuvre D, Pernet D, et al. Prevalence and risk factors for chronic bronchitis and farmer's lung in French dairy farmers. Br J Ind Med 1993; 50: 941-944.
225. Depierre A, Dalphin JC, Pernet D, et al. Epidemiological study of farmer's lung in five districts of the French Doubs province. Thorax 1988; 43: 429-435.
226. Freedman PM, Ault B. Bronchial hyperreactivity to methacholine in farmers' lung disease. J Allergy Clin Immunol 1981; 67: 59-63.
227. Mönkäre S, Haahtela T, Ikonen M, et al. Bronchial hyperreactiv-ity to inhaled histamine in patients with farmers' lung. Lung 1981; 145-151.
228. Kokkarinen JI, Tukiainen HO, Terho EO. Recovery of pulmonary function in farmer's lung: a five-year follow-up study. Am Rev Respir Dis 1993; 147: 793-796.
229. Kokkarinen JI, Tukiainen HO, Terho EO. Asthma in patients with farmer's lung during a five-year follow-up. Scand J Work Environ Health 1997; 23: 149-151.
230. Braun SR, doPico GA, Tsiatis A, et al. Famer's lung disease: long-term clinical and physiologic outcome. Am Rev Respir Dis 1979; 119: 185-191.
231. Fink JN, Ortega HG, Reynolds HY, et al. Needs and opportunities for research in hypersensitivity pneumonitis. Am J Respir Crit Care Med 2005; 171: 792-798.
232. Ameille J, Letourneux M, Paris C, et al. Does asbestose exposure cause airway obstruction, in the absence of confirmed asbestosis? Am J Respir Crit Care Med 2010; 182: 526-530.
233. de la Hoz RE. Occupational lower airway disease in relation to World Trade Center inhalation exposure. Cur Opin Allergy Clin Immunol 2011; 11: 97-102.
234. King MS, Eisenberg R, Newman JH, et al. Constrictive bronchiolitis in soldiers returning from Iraq and Afghanistan. N Engl J Med 2011; 365: 222-230.